Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients.


Journal

Clinical and experimental rheumatology
ISSN: 0392-856X
Titre abrégé: Clin Exp Rheumatol
Pays: Italy
ID NLM: 8308521

Informations de publication

Date de publication:
Historique:
received: 15 04 2019
accepted: 01 07 2019
entrez: 30 8 2019
pubmed: 30 8 2019
medline: 8 10 2019
Statut: ppublish

Résumé

To analyse the frequency and characterise the systemic presentation of primary Sjögren's syndrome (SS) out of the ESSDAI classification in a large international, multi-ethnic cohort of patients. The Big Data Sjögren Project Consortium is an international, multicentre registry based on world-wide data-sharing and cooperative merging of pre-existing clinical SS databases from leading centres in clinical research in SS from the five continents. A list of 26 organ-by-organ systemic features not currently included in the ESSDAI classification was defined according to previous studies; these features were retrospectively recorded. Information about non-ESSDAI features was available in 6331 patients [5,917 female, mean age at diagnosis 52 years, mainly White (86.3%)]. A total of 1641 (26%) patients had at least one of the ESSDAI systemic features. Cardiovascular manifestations were the most frequent organ-specific group of non-ESSDAI features reported in our patients (17% of the total cohort), with Raynaud's phenomenon being reported in 15%. Patients with systemic disease due to non-ESSDAI features had a lower frequency of dry mouth (90.7% vs. 94.1%, p<0.001) and positive minor salivary gland biopsy (86.7% vs. 89%, p=0.033), a higher frequency of anti-Ro/SSA (74.7% vs. 68.7%, p<0.001), anti-La/SSB antibodies (44.5% vs. 40.4%, p=0.004), ANA (82.7% vs. 79.5%, p=0.006), low C3 levels (17.4% vs. 9.7%, p<0.001), low C4 levels (14.4% vs. 9.6%, p<0.001), and positive serum cryoglobulins (8.6% vs. 5.5%, p=0.001). Systemic activity measured by the ESSDAI, clinESSDAI and DAS was higher in patients with systemic disease out of the ESSDAI in comparison with those without these features (p<0.001 for all comparisons). More than a quarter of patients with primary SS may have systemic manifestations not currently included in the ESSDAI classification, with a wide variety of cardiovascular, digestive, pulmonary, neurological, ocular, ENT (ear, nose, and throat), cutaneous and urological features that increase the scope of the systemic phenotype of the disease. However, the individual frequency of each of these non-ESSDAI features was very low, except for Raynaud's phenomenon.

Identifiants

pubmed: 31464664
pii: 14220

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

97-106

Auteurs

Soledad Retamozo (S)

Inst. De Investigaciones En Ciencias De La Salud (INICSA), Universidad Nacional de Córdoba (UNC), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Córdoba, and Inst. Universitario de Ciencias Biomédicas de Córdoba (IUCBC), Argentina.

Nihan Acar-Denizli (N)

Department of Statistics, Faculty of Science and Letters, Mimar Sinan Fine Arts University, Istanbul, Turkey.

Astrid Rasmussen (A)

Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Ildikó Fanny Horváth (IF)

Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Hungary.

Chiara Baldini (C)

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Roberta Priori (R)

Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Italy.

Pulukool Sandhya (P)

Department of Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India.

Gabriela Hernandez-Molina (G)

Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Subirán, México City, Mexico.

Berkan Armagan (B)

Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey.

Sonja Praprotnik (S)

Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia.

Marika Kvarnstrom (M)

Department of Medicine, Solna, Division of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.

Roberto Gerli (R)

Rheumatology Unit, Department of Medicine, University of Perugia, Italy.

Agata Sebastian (A)

Department of Rheumatology and Internal Medicine, Wroclaw Medical Hospital, Wroclaw, Poland.

Roser Solans (R)

Department of Internal Medicine, Hospital Vall d'Hebron, Barcelona, Spain.

Maureen Rischmueller (M)

Department of Rheumatology, The Queen Elizabeth Hospital and University of Adelaide, South Australia, Australia.

Sandra G Pasoto (SG)

Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil.

Valeria Valim (V)

Department of Medicine, Federal University of Espírito Santo, Vitória, Brazil.

Gunnel Nordmark (G)

Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden.

Aike Kruize (A)

Department of Rheumatology and Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands.

Hideki Nakamura (H)

Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan.

Benedikt Hofauer (B)

Otorhinolaryngology, Head and Neck Surgery, Technical University Munich, Munich, Germany.

Roberto Giacomelli (R)

Clinical Unit of Rheumatology, University of l'Aquila, School of Medicine, L'Aquila, Italy.

Virginia Fernandes Moça Trevisani (V)

Federal University of São Paulo, Brazil.

Valerie Devauchelle-Pensec (V)

Rheumatology Department, Brest University Hospital, France.

Fabiola Atzeni (F)

IRCCS Galeazzi Orthopedic Institute, Milan and Rheumatology Unit, University of Messina, Italy.

Tamer A Gheita (TA)

Rheumatology Department, Kasr Al Ainy School of Medicine, Cairo University, Egypt.

Sandra Consani-Fernández (S)

Internal Medicine, Hospital Maciel, and Universidad de la República (UdelaR), Montevideo, Uruguay.

Antonia Szántó (A)

Division of Clinical Immunology, Faculty of Medicine, University of Debrecen, Hungary.

Kathy Sivils (K)

Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.

Angelina Gattamelata (A)

Department of Internal Medicine and Medical Specialties, Rheumatology Clinic, Sapienza University of Rome, Italy.

Debashish Danda (D)

Department of Clinical Immunology & Rheumatology, Christian Medical College & Hospital, Vellore, India.

Levent Kilic (L)

Department of Internal Medicine, Hacettepe University, Faculty of Medicine, Ankara, Turkey.

Elena Bartoloni (E)

Rheumatology Unit, Department of Medicine, University of Perugia, Perugia, Italy.

Stefano Bombardieri (S)

Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Italy.

Jorge Sánchez-Guerrero (J)

Immunology and Rheumatology Department, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Subirán, México City, Mexico.

Marie Wahren-Herlenius (M)

Department of Medicine, Solna, Division of Experimental Rheumatology, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden.

Xavier Mariette (X)

Centre for Immunology of Viral Infections and Autoimmune Diseases, Université Paris-Sud, INSERM UMR1184, Assistance Publique - Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, France.

Manuel Ramos-Casals (M)

Sjögren's Syndrome Research Group (AGAUR), Laboratory of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Department of Autoimmune Diseases, ICMiD, University of Barcelona, Hospital Clínic, Spain. mramos@clinic.cat.

Pilar Brito-Zerón (P)

Sjögren's Syndrome Res. Group (AGAUR), Lab. of Autoimmune Diseases Josep Font, IDIBAPS-CELLEX, Dept. of Autoimmune Diseases, ICMiD, Univ. of Barcelona, Hospital Clínic, and Autoimmune Diseases Unit, Dept. of Medicine, Hosp. CIMA-Sanitas, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH